Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorder
First author：Yuzhen Wei
Corresponding author：Linlin Yin,Xinghu Zhang
essential_information
- Person in charge：Yuzhen Wei
- Data Sources： OTHERS
- Number of papers：OTHERS20190049
- Published time：2018-10-22
2018-10-22
Published articles
Journal：BioMed Research International
Publication type: Original Contributions
IF(IF): 3.411
PMID: 30426010 Link To Pubmed Full text Download
Background And Purpose
Astrocytic impairment is a pathologic feature of neuromyelitis optica spectrum disorder (NMOSD). S100B and glial fbrillary acidic protein (GFAP) are the two most commonly used astrocytic markers. Te aim of this study was to evaluate whether CSF-S100B could serve as a marker of NMOSD.
Method
We enrolled 49 NMOSD patients [25 aquaporin-4 antibody (AQP4-Ab)–positive, 8 myelinoligodendrocyte glycoprotein antibody (MOG-Ab)-positive, and 16 seronegative patients], 12 multiple sclerosis (MS) patients, and 15 other noninfammatory neurological diseases (OND) patients. Te CSF levels of S100B and GFAP were measured by ELISA.
Conclusion
CSF-S100B might be a potential candidate biomarker for NMOSD in discriminating, evaluating severity, and predicting disability.
Main results
Both CSF-S100B and GFAP levels signifcantly discriminated NMOSD from MS [area under curve (AUC) = 0.839 and 0.850, respectively] and OND (AUC = 0.839 and 0.850, respectively). Te CSF-S100B levels diferentiated AQP4-Ab–positive NMOSD from MOGAb–positive NMOSD with higher accuracy than the CSF-GFAP levels (AUC=0.865 and 0.772, respectively). Te CSF-S100B levels also signifcantly discriminated MOG-Ab–positive patients from seronegative patients (AUC = 0.848). Both CSF-S100B and GFAP levels were correlated with the Expanded Disability Status Scale (EDSS) during remission. Only the CSF-S100B levels were correlated with the CSF WBC count and the EDSS during attack. Te levels of CSF-S100B seemed to have a longer lasting time than the levels of CSF-GFAP, which may beneft patients who present late.